Rostral Migratory Stream Neural Progenitors is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value | [1]
|----------|-------| [2]
| Location | Forebrain, SVZ to olfactory bulb | [3]
| Type | Neural progenitor pathway | [4]
| Function | Adult neurogenesis, olfactory bulb interneuron production | [5]
| Cell Types | Neuroblasts, astrocytes, ependymal cells | [6]
| Direction | Rostral (noseward) migration | [7]
| Length | Approximately 5-8 mm in rodents | [8]
The Rostral Migratory Stream (RMS) is a specialized, highly conserved pathway in the adult mammalian brain through which neural progenitor cells migrate from the subventricular zone (SVZ) of the lateral ventricles to the olfactory bulb. This stream represents the principal neurogenic niche in the adult brain, continuously generating new neurons that integrate into olfactory circuits 1]. [9]
In humans, the RMS extends from the SVZ in the wall of the lateral ventricle, through the striatum, and terminates in the olfactory bulb. The pathway contains chains of neuroblasts ensheathed by astrocytic tunnels, creating a unique microenvironment that facilitates migration while protecting neurons from the surrounding brain parenchyma 2]. [10]
The RMS consists of several distinct cellular compartments. The SVZ is the primary neurogenic niche, containing neural stem cells (B1 astrocytes), transit-amplifying cells (C cells), and neuroblasts (A cells). B1 cells are slowly dividing astrocytes that can generate all three cell types in the SVZ lineage 3. [11]
Neuroblasts (A cells) are the predominant migratory cell type in the RMS. These cells express doublecortin (DCX), PSA-NCAM, and TuJ1 (βIII-tubulin), markers of immature neurons. They migrate in chains, using neighbor cells as substrates through a process called chain migration 4. [12]
Astrocytes (B2 cells) form the glial tubes that surround migrating neuroblast chains. These astrocytes express glial fibrillary acidic protein (GFAP) and provide structural support, guidance cues, and regulate the extracellular environment 5]. [13]
Ependymal cells (E cells) line the ventricular surface and contribute to the stem cell niche by secreting cerebrospinal fluid (CSF) components and signaling molecules. The multiciliated ependymal epithelium creates directional CSF flow that influences stem cell behavior 6. [14]
Neural stem cells in the SVZ express a characteristic molecular signature. The transcription factor Pax6 is essential for maintaining the neurogenic potential of SVZ stem cells and regulating their differentiation into olfactory bulb interneurons 7]. Other key transcription factors include Dlx2, Gsx2 (Mash1), and Sp8, which drive neuroblast specification and migration 8. [15]
Epidermal growth factor (EGF) and fibroblast growth factor (FGF) signaling are critical for SVZ cell proliferation and differentiation. EGF stimulates transit-amplifying cell expansion, while FGF promotes neuronal differentiation 9]. [16]
The extracellular matrix in the RMS contains molecules that facilitate neuroblast migration. Tenascin-C, polysialylated neural cell adhesion molecule (PSA-NCAM), and vitronectin provide guidance cues and cell adhesion support 10. [17]
Slit-Robo and netrin-Unc5 signaling provide chemorepulsive cues that guide neuroblast migration through the RMS. Slit proteins secreted from the septum repel neuroblasts away from the ventral telencephalon, while netrin promotes ventral migration 11]. [18]
Neuroblast migration in the RMS occurs through a process called chain migration, in which cells move in close contact with each other rather than as individual cells. This is facilitated by cell adhesion molecules including N-cadherin and NCAM, which mediate homophilic interactions between neighboring neuroblasts 12. [19]
The leading process of migrating neuroblasts extends in the direction of migration, with the cell soma following through a process called somal translocation. Cytoskeletal dynamics, regulated by small GTPases (Rac1, Cdc42, RhoA), drive process extension and actomyosin contraction 13]. [20]
Migrating neuroblasts receive guidance cues from surrounding astrocytes and blood vessels. Blood vessels in the RMS provide physical scaffolds and secrete factors including brain-derived neurotrophic factor (BDNF) that promote neuroblast survival and migration 14. [21]
Upon reaching the olfactory bulb, neuroblasts differentiate into several types of interneurons: granule cells (GABAergic), periglomerular cells (dopaminergic), and short-axon cells. This diversity is regulated by spatial patterning in the SVZ and specific transcription factor programs 15. [22]
Newly arrived neuroblasts extend dendrites and form synaptic connections with existing neurons. They receive synaptic input from olfactory sensory neurons and centrifugal fibers, indicating functional integration into olfactory circuits 16. [23]
Approximately 50-70% of new olfactory bulb neurons survive to become functionally integrated, with the rest undergoing apoptosis during a critical period 2-4 weeks after arrival. This pruning ensures appropriate circuit matching 17. [24]
The RMS is affected in Alzheimer's disease (AD), with studies showing reduced neurogenesis in the SVZ and altered RMS function. Amyloid-beta plaques and tau pathology are present in the SVZ and RMS regions, suggesting direct involvement of the neurogenic niche 18. [25]
Impaired neurogenesis in AD may contribute to olfactory dysfunction, which is an early symptom of the disease. Up to 90% of AD patients exhibit olfactory deficits, potentially reflecting RMS and olfactory bulb pathology 19. [26]
Transgenic AD mouse models show reduced SVZ proliferation and neuroblast migration, with amyloid-beta directly inhibiting neural stem cell function. Restoring neurogenesis in these models improves cognitive function, suggesting therapeutic potential 20. [27]
Olfactory dysfunction is a prodromal marker in Parkinson's disease (PD), often preceding motor symptoms by years. The RMS and olfactory bulb show alpha-synuclein pathology in PD patients, with Lewy bodies present in olfactory bulb interneurons 21. [28]
Neurogenesis in the SVZ is impaired in PD, possibly due to alpha-synuclein toxicity and neuroinflammation. Dopaminergic signaling normally promotes neurogenesis, and its loss in PD may contribute to reduced olfactory bulb neuron production 22. [29]
Elevated levels of inflammatory cytokines in the PD brain, including TNF-α and IL-1β, suppress SVZ neural stem cell proliferation and neuroblast migration. Anti-inflammatory treatments show promise in preclinical models for restoring neurogenesis 23. [30]
Huntington's disease (HD) shows severe impairment of RMS neurogenesis. The mutant huntingtin protein disrupts neural stem cell function through multiple mechanisms: transcriptional dysregulation, mitochondrial dysfunction, and impaired autophagy 24. [31]
HD mouse models demonstrate reduced SVZ proliferation, impaired neuroblast migration, and decreased olfactory bulb neuron integration. These deficits may contribute to the olfactory dysfunction observed in HD patients, which correlates with disease severity 25.
In multiple sclerosis (MS), demyelination in the RMS and SVZ regions may impair neurogenesis. While the RMS can regenerate after injury, chronic neuroinflammation limits functional recovery. Remyelination therapies may need to address both oligodendrocyte and neuronal replacement 26.
The RMS shows enhanced neurogenesis following brain injury, representing an endogenous repair mechanism. Ischemic stroke in the striatum stimulates SVZ neuroblast migration toward the damaged area, where some neurons can differentiate and replace lost striatal neurons 27.
However, most stroke-directed neuroblasts fail to fully integrate, often dying before synaptic connection. Enhancing survival and functional integration of these cells is an active area of therapeutic research 28.
Understanding RMS biology has led to several therapeutic strategies. Stem cell transplantation into the RMS or SVZ could replace lost neurons in neurodegenerative diseases. However, ensuring proper migration, differentiation, and functional integration remains challenging 29.
Small molecules that enhance neurogenesis, including antidepressants (SSRIs), mood stabilizers (lithium), and exercise mimetics, have shown promise in preclinical models. These agents increase SVZ proliferation and neuroblast output 30.
Gene therapy approaches to enhance neurotrophic factor expression (BDNF, GDNF, NGF) in the SVZ/RMS could support neuron survival and differentiation. Viral vector delivery of these factors is being explored for AD, PD, and HD 31.
Modulating the extracellular environment to enhance neuroblast migration is another approach. Inhibiting factors that impede migration (chondroitin sulfate proteoglycans, myelin debris) while enhancing positive cues (BDNF, EGF) could improve functional outcomes 32.
The study of Rostral Migratory Stream Neural Progenitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sanford SD, Zhao M, Saha K, et al. The human rostral migratory stream. Brain Struct Funct. 2018. 2018. ↩︎
Doetsch F, Caill I, Lim DA, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells. Cell. 1999. 1999. ↩︎
Rousselot P, Lois C, Alvarez-Buylla A. Chain formation in the adult mouse subventricular zone. J Comp Neurol. 1995. 1995. ↩︎
García-Verdugo JM, Doetsch F, Wichterle H, et al. The astrocytic tube in the RMS. J Neurobiol. 1998. 1998. ↩︎
Sawamoto K, Wichterle H, Gonzalez-Perez O, et al. New neurons from the SVZ. Cell. 2006. 2006. ↩︎
Hack MA, Saghatelyan A, de Chevigny A, et al. Pax6 controls odorant receptor expression. Nat Neurosci. 2005. 2005. ↩︎
Young KM, Fogarty M, Kessaris N, Richardson WD. Dlx2 and Gsx2 specify olfactory bulb interneurons. J Neurosci. 2007. 2007. ↩︎
Doetsch F. EGF and FGF in the SVZ neurogenic niche. Prog Neurobiol. 2003. 2003. ↩︎
Miragall F, Husmann J, Albiez G, et al. PSA-NCAM in the RMS. Dev Brain Res. 1988. 1988. ↩︎
Wu W, Wong K, Chen J, et al. Slit-Robo guidance in RMS. Nature. 1999. 1999. ↩︎
Kazanis I. Neuroblast chain migration in the adult brain. Trends Neurosci. 2019. 2019. ↩︎
Saha B, Javaherian M, Schafer S, et al. Cytoskeletal mechanisms of neuroblast migration. J Neurosci. 2012. 2012. ↩︎
Snapyan M, Lemasson M, Brill MS, et al. Blood vessels guide neuroblast migration. Cell Stem Cell. 2009. 2009. ↩︎
Lledo PM, Saghatelyan A. Integrating new neurons into adult olfactory circuits. Nat Neurosci. 2005. 2005. ↩︎
Belluzzi O, Benedusi M, Cellerino A. Synaptic integration of new neurons in the OB. J Neurosci. 2003. 2003. ↩︎
Petreanu L, Alvarez-Buylla A. Maturation and death of adult-born OB neurons. J Neurosci. 2002. 2002. ↩︎
Ekonomou A, Savva GM, Romunc P, et al. Neurogenesis in AD. J Alzheimers Dis. 2015. 2015. ↩︎
Devanand DP, Michaels-Marston KS, Liu X, et al. Olfactory deficits in AD. Am J Psychiatry. 2000. 2000. ↩︎
Choi SH, Tanzi RE. Neurogenesis in AD models. Cell Stem Cell. 2018. 2018. ↩︎
Braak H, Del Tredici K. Olfactory pathology in PD. Ann N Y Acad Sci. 2009. 2009. ↩︎
Höglinger GU, Rizk P, Muriel MP, et al. Dopamine regulates SVZ neurogenesis. Nat Neurosci. 2004. 2004. ↩︎
Perez-Catalan NA, Mate-Aparicio P, Streit WJ. Neuroinflammation and neurogenesis in PD. Neurobiol Aging. 2020. 2020. ↩︎
Tattersfield AS, Croon RJ, Liu YW, et al. Neurogenesis in HD. Brain. 2007. 2007. ↩︎
Moustafa AA, Hewedi DH, Eissa AM, et al. Olfactory dysfunction in HD. J Huntingtons Dis. 2016. 2016. ↩︎
Nait-Oumesmar B, Picard-Riera N, Kerninon C, et al. The SVZ in demyelinating diseases. J Neuroimmunol. 2008. 2008. ↩︎
Arvidsson A, Collin T, Kirik D, et al. Stroke-induced neurogenesis. Nat Neurosci. 2002. 2002. ↩︎
Kokaia Z, Lindvall O. Stroke and neurogenesis. Cell Stem Cell. 2013. 2013. ↩︎
Gage FH, Temple S. Neural stem cell therapy. Nat Med. 2013. 2013. ↩︎
Morse SJ, Butler AA, Davis RL. Enhancing neurogenesis. Pharmacol Ther. 2020. 2020. ↩︎
Kordower JH, Bjorklund A. Gene therapy for neurodegenerative disease. Nat Rev Neurol. 2019. 2019. ↩︎
Kaneko N, Sawada M, Sawamoto K. Mechanisms of neuroblast migration. J Neurosci Res. 2020. 2020. ↩︎